The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 study of first-line pembrolizumab in elderly patients with non-small cell lung cancer expressing high PD-L1.
 
Kosuke Hamai
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; Ono Pharmaceutical
 
Takeshi Masuda
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Kirin International; Kyowa Kirin International; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - MSD K.K
 
Kazunori Fujitaka
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Kyowa Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Tomoko Suzuki
Honoraria - Chugai Pharma
 
Naoko Matsumoto
No Relationships to Disclose
 
Mirai Matsumura
No Relationships to Disclose
 
Shoko Isoyama
No Relationships to Disclose
 
Sayaka Ueno
No Relationships to Disclose
 
Mineyo Mito
No Relationships to Disclose
 
Kakuhiro Yamaguchi
Honoraria - Chugai Pharma; Ono Pharmaceutical
Research Funding - AstraZeneca Canada
 
Shinjiro Sakamoto
Honoraria - Ono Pharmaceutical
 
Reo Kawano
No Relationships to Disclose
 
Ken Masuda
No Relationships to Disclose
 
Ryohei Nishino
Honoraria - AstraZeneca Japan; Chugai Pharma; Kyorin
 
Nobuhisa Ishikawa
Honoraria - Chugai Pharma; MSD; Ono Pharmaceutical
 
Masahiro Yamasaki
Honoraria - Chugai Pharma; MSD; Ono Pharmaceutical
 
Noboru Hattori
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Kirin (Inst); Lilly (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)